Your browser doesn't support javascript.
loading
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer.
Noortman, Wyanne A; Aide, Nicolas; Vriens, Dennis; Arkes, Lisa S; Slump, Cornelis H; Boellaard, Ronald; Goeman, Jelle J; Deroose, Christophe M; Machiels, Jean-Pascal; Licitra, Lisa F; Lhommel, Renaud; Alessi, Alessandra; Woff, Erwin; Goffin, Karolien; Le Tourneau, Christophe; Gal, Jocelyn; Temam, Stéphane; Delord, Jean-Pierre; van Velden, Floris H P; de Geus-Oei, Lioe-Fee.
Affiliation
  • Noortman WA; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Aide N; TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.
  • Vriens D; Nuclear Medicine Department, Centre Hospitalier Universitaire de Caen, 14000 Caen, France.
  • Arkes LS; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Slump CH; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Boellaard R; Technical Medicine, Delft University of Technology, 2628 CD Delft, The Netherlands.
  • Goeman JJ; TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.
  • Deroose CM; Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
  • Machiels JP; Department of Biomedical Data Sciences, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
  • Licitra LF; Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
  • Lhommel R; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
  • Alessi A; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
  • Woff E; Department of Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, 20133 Milan, Italy.
  • Goffin K; Division of Nuclear Medicine, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium.
  • Le Tourneau C; Department of Nuclear Medicine-PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Gal J; Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), 1070 Bruxelles, Belgium.
  • Temam S; Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium.
  • Delord JP; Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, 75005 Paris, France.
  • van Velden FHP; Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06100 Nice, France.
  • de Geus-Oei LF; Department of Head and Neck Surgery Gustave Roussy, 94805 Villejuif, France.
Cancers (Basel) ; 15(10)2023 May 09.
Article in En | MEDLINE | ID: mdl-37345017
ABSTRACT

AIM:

To build and externally validate an [18F]FDG PET radiomic model to predict overall survival in patients with head and neck squamous cell carcinoma (HNSCC).

METHODS:

Two multicentre datasets of patients with operable HNSCC treated with preoperative afatinib who underwent a baseline and evaluation [18F]FDG PET/CT scan were included (EORTC n = 20, Unicancer n = 34). Tumours were delineated, and radiomic features were extracted. Each cohort served once as a training and once as an external validation set for the prediction of overall survival. Supervised feature selection was performed using variable hunting with variable importance, selecting the top two features. A Cox proportional hazards regression model using selected radiomic features and clinical characteristics was fitted on the training dataset and validated in the external validation set. Model performances are expressed by the concordance index (C-index).

RESULTS:

In both models, the radiomic model surpassed the clinical model with validation C-indices of 0.69 and 0.79 vs. 0.60 and 0.67, respectively. The model that combined the radiomic features and clinical variables performed best, with validation C-indices of 0.71 and 0.82.

CONCLUSION:

Although assessed in two small but independent cohorts, an [18F]FDG-PET radiomic signature based on the evaluation scan seems promising for the prediction of overall survival for HNSSC treated with preoperative afatinib. The robustness and clinical applicability of this radiomic signature should be assessed in a larger cohort.
Key words

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Type of study: Prognostic_studies Language: En Year: 2023 Type: Article